| 2026-08-18 | Press release | PDF Version |
| 2026-08-18 | Press release | Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzge |
| 2026-08-14 | Presentation | Company Presentation |
| 2026-08-13 | Press release | Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates |
| 2026-08-11 | Press release | Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced |
| 2026-08-10 | Press release | Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board |
| 2026-07-27 | Press release | Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Sma |
| 2026-07-20 | Press release | Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology |
| 2026-06-25 | Press release | Eikon Therapeutics to Join the Russell 3000® Index |
| 2026-06-08 | Press release | Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors |
| 2026-05-30 | Press release | Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinic |
| 2026-05-21 | Press release | Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American S |
| 2026-05-11 | Press release | Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates |
| 2026-03-30 | Press release | Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Upd |
| 2026-02-04 | Press release | Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering |
| 2025-10-15 | Press release | PDF Version |
| 2025-10-15 | Press release | Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 |
| 2025-05-29 | Press release | PDF Version |
| 2025-01-07 | Press release | PDF Version |
| 2025-01-07 | Press release | Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 2024-08-26 | Press release | PDF Version |
| 2024-08-26 | Press release | Eikon Therapeutics Management to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference |
| 2024-06-06 | Press release | PDF Version |
| 2024-06-06 | Press release | Eikon Therapeutics to Present at the 45th Annual Goldman Sachs Global Healthcare Conference |
| 2024-05-28 | Press release | PDF Version |
| 2024-05-28 | Press release | Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annu |
| 2024-01-08 | Press release | PDF Version |
| 2024-01-08 | Press release | Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference |
| 2024-01-08 | Press release | Eikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference |
| 2023-12-18 | Press release | PDF Version |
| 2023-06-01 | Press release | PDF Version |
| Press release | Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress |
| Press release | Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline |